# Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity

> **NCT04894435** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Canadian Immunization Research Network** · enrollment: 669 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** mRNA-1273 SARS-CoV-2 vaccine
- **BIOLOGICAL:** BNT162b2
- **BIOLOGICAL:** ChAdOx1-S [recombinant]
- **OTHER:** 0, 28 day schedule
- **OTHER:** 0, 112 day schedule
- **BIOLOGICAL:** Covifenz

## Key facts

- **NCT ID:** NCT04894435
- **Lead sponsor:** Canadian Immunization Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-20
- **Primary completion:** 2024-11-15
- **Final completion:** 2025-08-01
- **Target enrollment:** 669 (ACTUAL)
- **Last updated:** 2025-03-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04894435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04894435, "Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04894435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*